Apotex Can't Join Nearly Done Orphan Drug Suit, Eagle Says
Apotex Inc. waited until litigation over the U.S. Food and Drug Administration's denial of orphan drug exclusivity for Eagle Pharmaceuticals Inc.'s chemotherapy injection Bendeka was nearly over before saying it needed...To view the full article, register now.
Already a subscriber? Click here to view full article